Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 86 |
| Active Pipeline (Recruiting Now) | 22 (14) |
| Completed vs Stopped Early | 49 / 15 (17.4%) |
| Median Closed Actual Enrollment | 111 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 30 (6 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UCI Health and Chao Family Comprehensive Cancer Center | Orange, CA | 2 |
| Ohio State University Comprehensive Cancer Center | Columbus, OH | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04115293 | Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis | Phase III | COMPLETED |
| NCT04025632 | Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy | Phase II | TERMINATED |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the UCB Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.